ARS Pharmaceuticals, Inc. (SPRY) Net margin 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) net profit margin by fiscal year — reported net income divided by reported revenue.
-203.3%FY2025 · since FY2021: -367.7% → -203.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -203.3% | -212.2 pp |
| FY2024 | 9.0% | +181225.6 pp |
| FY2023 | -181216.7% | -178581.3 pp |
| FY2022 | -2635.4% | -2267.8 pp |
| FY2021 | -367.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →